Skip to main content

Table 2 PCR-adjusted and unadjusted cure rates of the study participants at day-42 at Dafra health district medical centre, Burkina Faso, 2008–2010

From: In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

Outcome: day 42 AL ASAQ Difference (CI 95%) p-value
Variables
PCR corrected efficacy outcome—no. (%)
Per protocol population (N = 420) n (%) 213 207
 Adequate clinical and parasitological response 194 (91.1) 203 (98.1) − 7 (− 11.0 to − 2.7) < 0.0006
 Early treatment failure 0 (0.0) 0 (0)
 Late clinical failure 0 (0.0) 0 (0)
 Late parasitological failure 19 (8.9) 4 (1.9)
 Total number of failure 19 (8.9) 4 (1.9)
Not corrected for reinfection n (%)
 Adequate clinical and parasitological response 106 (49.8) 147 (71.0) − 22 (− 31.1 to − 12.9) < 0.0001
 Early treatment failure 0 (0) 0 (0)
 Late clinical failure 32 (15.0) 22 (10.6)
 Late parasitological failure 75 (35.2) 38 (18.4)
 Total number of failure 107 (50.2) 60 (28.9)
Intent-to-treat population (N = 440) 220 220
 PCR-adjusted
 Total number of patients n 194 203   
 Adequate clinical and parasitological response % (95% CI) 88.2 (83.2–91.8 92.3 (87.9–95.2) − 4.1 (− 9.8 to − 1.5) 0.148
 PCR-unadjusted
 Total number of patients n 106 147
 Adequate clinical and parasitological response % (95% CI) 48.2 (41.6–54.8) 66.8 (60.3–72.8) − 18.6 (− 27.4 to 9.4) < 0.001
  1. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, CI 95% confident interval, n number, % percentage